OMEROS CORP Interest Expense Nonoperating
OMEROS CORP (OMER) reported Interest Expense Nonoperating of $7.58 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-12
- OMEROS CORP interest expense nonoperating for the quarter ending 2026-06-30 was $7.58M, a 50466.67% increase year-over-year.
- OMEROS CORP interest expense nonoperating for the quarter ending 2026-03-31 was $5.89M, a 61.30% increase year-over-year.
- OMEROS CORP interest expense nonoperating for the quarter ending 2025-12-31 was $8.73M, a 174.66% increase year-over-year.
- OMEROS CORP interest expense nonoperating for the quarter ending 2025-09-30 was -$13.36M, a 429.59% decline year-over-year.
- OMEROS CORP interest expense nonoperating for fiscal 2025 was -$960.00K, a 103.89% decline from fiscal 2024.
- OMEROS CORP interest expense nonoperating for fiscal 2024 was $24.68M, a 20.00% decline from fiscal 2023.
- OMEROS CORP interest expense nonoperating for fiscal 2023 was $30.84M, a 35.86% increase from fiscal 2022.
- OMEROS CORP interest expense nonoperating for fiscal 2022 was $22.70M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.58M 10-Q · filed 2026-08-12 | $13.48M 10-Q · filed 2026-08-12 | $22.20M derived: sum of 3 quarters · filed 2026-08-12 | $8.85M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $5.89M 10-Q · filed 2026-05-13 | $14.62M derived: sum of 2 quarters · filed 2026-05-13 | $1.26M derived: sum of 3 quarters · filed 2026-05-13 | $1.28M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $8.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$4.63M derived: sum of 2 quarters · filed 2026-03-31 | -$4.61M derived: sum of 3 quarters · filed 2026-08-12 | -$960.00K 10-K · filed 2026-03-31 |
| 2025-09-30 | -$13.36M 10-Q · filed 2025-11-13 | -$13.34M derived: sum of 2 quarters · filed 2026-08-12 | -$9.69M 10-Q · filed 2025-11-13 | -$6.51M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $15.00K 10-Q · filed 2026-08-12 | $3.67M 10-Q · filed 2026-08-12 | $6.85M derived: sum of 3 quarters · filed 2026-08-12 | $10.90M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $3.65M 10-Q · filed 2026-05-13 | $6.83M derived: sum of 2 quarters · filed 2026-05-13 | $10.88M derived: sum of 3 quarters · filed 2026-05-13 | $20.10M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $3.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $7.23M derived: sum of 2 quarters · filed 2026-03-31 | $16.44M derived: sum of 3 quarters · filed 2026-03-31 | $24.68M 10-K · filed 2026-03-31 |
| 2024-09-30 | $4.05M 10-Q · filed 2025-11-13 | $13.27M derived: sum of 2 quarters · filed 2025-11-13 | $21.50M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $9.21M 10-Q · filed 2025-08-14 | $17.45M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $8.23M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $30.84M 10-K · filed 2026-03-31 | |||
| 2022-12-31 | $22.70M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |